BEAM is trading 4.5% up at $36.91 after investors reacted positively to new Phase 1/2 data for its BEAM-302 base-editing program in alpha-1 antitrypsin deficiency.
- The company highlighted durable single-dose efficacy, sustained alpha-1 antitrypsin increases, and a favorable safety profile.
- Broader strength across the biotechnology sector is providing additional support to the stock's upward move.